Effects of poly(ethyleneglycol)-modified hemoglobin vesicles on agonist-induced platelet aggregation and RANTES release in vitro.
We studied the effects of hemoglobin-vesicles modified with PEG (PEG-HbV), a type of liposome-encapsulated hemoglobin (LEH), on human platelet functions in vitro. The effect of a low concentration of PEG-HbV (Hb; 5.8 mg/dl) was assessed by examining an agonist-induced aggregation response, and that of relatively high concentrations of PEG-HbV (Hb; 0.29, 1 and 2 g/dl) by measuring the release of RANTES (Regulated upon activation, normal T-cell expressed and presumably secreted) from platelets, which is regarded as a marker of platelet activation. The preincubation of platelets with PEG-HbV at 5.8 mg/dl of Hb did not affect platelet aggregation induced by collagen, thrombin and ristocetin. The pretreatment of platelet-rich plasma (PRP) with PEG-HbV at concen trations up to 2 g/dl of Hb had no aberrant effects on the collagen-induced RANTES release. Furthermore, the collagen-induced release of RANTES from PRP was not affected by longer incubation with PEG-HbV at 2 g/dl of Hb. The basal levels of RANTES from PRP were unchanged in the presence of PEG-HbV. These results suggest that PEG-HbV, at the concentrations studied, have no aberrant effects on platelet functions in the presence of plasma.
Wakamoto
S
S
Hokkaido Red Cross Blood Center, Sapporo, Japan.
Fujihara
M
M
Abe
H
H
Sakai
H
H
Takeoka
S
S
Tsuchida
E
E
Ikeda
H
H
Ikebuchi
K
K
D018946:Chemokine CCL5 / Q000378:metabolism*; D003029:Coagulants; D003094:Collagen; D004339:Drug Compounding; D006454:Hemoglobins / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*; D011092:Polyethylene Glycols / Q000494:pharmacology*; D012310:Ristocetin; D013917:Thrombin
D018946:Chemokine CCL5; D003029:Coagulants; D006454:Hemoglobins; C109960:PEG-hemoglobin; D012310:Ristocetin; D011092:Polyethylene Glycols; D003094:Collagen; D013917:Thrombin